Bausch + Lomb Corp
BLCO16.950USD
+0.050+0.30%
收盘 12/19, 16:00（美东）报价延迟15分钟
6.00B总市值
亏损市盈率 TTM
关于 Bausch + Lomb Corp 公司
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Bausch + Lomb Corp简介
公司代码BLCO
公司名称Bausch + Lomb Corp
上市日期May 06, 2022
CEOSaunders (Brenton L)
员工数量13500
证券类型Ordinary Share
年结日May 06
公司地址520 Applewood Crescent
城市VAUGHAN
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Canada
邮编L4K 4B4
电话19082552864
网址https://ir.bausch.com/
公司代码BLCO
上市日期May 06, 2022
CEOSaunders (Brenton L)
Bausch + Lomb Corp公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
股东统计
更新时间: 11月22日 周六
更新时间: 11月22日 周六
持股股东
股东类型
持股股东
持股股东
占比
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
其他
8.54%
持股股东
持股股东
占比
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
其他
8.54%
股东类型
持股股东
占比
Corporation
87.66%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.07%
Research Firm
1.67%
Investment Advisor
1.65%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bausch Health Companies Inc
310.45M
87.68%
--
--
Mar 24, 2025
Deutsche Bank Securities Inc.
3.41M
0.96%
-89.90K
-2.57%
Jun 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
2.52M
0.71%
+2.52M
--
Jun 30, 2025
GoldenTree Asset Management, LP
2.58M
0.73%
+334.92K
+14.90%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
+728.68K
+38.79%
Jun 30, 2025
Fidelity Management & Research Company LLC
771.84K
0.22%
+771.84K
--
Jun 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
+1.05M
+210.77%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
查看更多
Ballast Small/Mid Cap ETF
占比1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
占比0.03%
BNY Mellon US Small Cap Core Equity ETF
占比0.03%
Schwab Fundamental International Small Equity ETF
占比0%
Goldman Sachs MarketBeta US 1000 Equity ETF
占比0%
Invesco Zacks Mid-Cap ETF
占比0%
QRAFT AI-Enhanced US Large Cap ETF
占比0%
AltShares Event-Driven ETF
占比0%
DFA Dimensional International Core Equity 2 ETF
占比0%
BNY Mellon US Mid Cap Core Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Bausch + Lomb Corp的前五大股东是谁？
Bausch + Lomb Corp 的前五大股东如下：
Bausch Health Companies Inc持有股份：310.45M，占总股份比例：87.68%。
Deutsche Bank Securities Inc.持有股份：3.41M，占总股份比例：0.96%。
Alberta Investment Management Corporation持有股份：3.27M，占总股份比例：0.92%。
Oaktree Capital Management, L.P.持有股份：2.52M，占总股份比例：0.71%。
GoldenTree Asset Management, LP持有股份：2.58M，占总股份比例：0.73%。
Bausch Health Companies Inc持有股份：310.45M，占总股份比例：87.68%。
Deutsche Bank Securities Inc.持有股份：3.41M，占总股份比例：0.96%。
Alberta Investment Management Corporation持有股份：3.27M，占总股份比例：0.92%。
Oaktree Capital Management, L.P.持有股份：2.52M，占总股份比例：0.71%。
GoldenTree Asset Management, LP持有股份：2.58M，占总股份比例：0.73%。
Bausch + Lomb Corp的前三大股东类型是什么？
Bausch + Lomb Corp 的前三大股东类型分别是：
Bausch Health Companies Inc
Icahn Enterprises LP
Deutsche Bank Securities Inc.
Bausch Health Companies Inc
Icahn Enterprises LP
Deutsche Bank Securities Inc.
有多少机构持有Bausch + Lomb Corp(BLCO)的股份？
截至2025Q4，共有247家机构持有Bausch + Lomb Corp的股份，合计持有的股份价值约为42.63M，占公司总股份的17.16%。与2025Q3相比，机构持股有所增加，增幅为-2.27%。
哪个业务部门对Bausch + Lomb Corp的收入贡献最大？
在FY2025Q2，OTC业务部门对Bausch + Lomb Corp的收入贡献最大，创收482.00M，占总收入的37.72%。
